9. Minimal Residual Disease
Breast Cancer 2026 addresses the importance of minimal residual disease, referring to small numbers of cancer cells that remain after treatment and may contribute to recurrence. Sensitive detection methods are essential for long-term monitoring.
Supports earlier intervention and improved patient outcomes through precise disease surveillance.
Key Highlights:
9.1 Residual Tumor Detection
9.2 Liquid Biopsy Applications
9.3 Disease Monitoring
9.4 Recurrence Prediction
9.5 Clinical Risk Assessment